OncoSil Medical Secures $8.7M for Pancreatic Cancer Device Expansion

OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.

OncoSil Medical Ltd has announced an $8.7 million capital raise to accelerate the commercialization of its pancreatic cancer treatment device. The funds will support ongoing clinical trials and commercialization efforts, with a focus on expanding market access in Europe and existing jurisdictions. The capital raise includes a placement and a Share Purchase Plan (SPP), with strong backing from institutional investors, including Pengana High Conviction Equities Fund. The completion of two major clinical trials, PANCOsil and TRIPP-FFX, is expected to significantly enhance the company’s market access and operational cash flow by the second half of 2026.

More about OncoSil Medical Ltd

OncoSil Medical Ltd is a company in the medical device industry, focusing on developing treatments for pancreatic cancer. Their primary product is the OncoSil™ device, which is used in conjunction with chemotherapy to treat pancreatic cancer. The company is actively working on expanding its market presence in Europe and other existing geographies.

Technical Sentiment Signal: Sell

Current Market Cap: A$16.12M

For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.